Free Annual Reports
St Jude Medical Third Quarter Earnings Preview
Tickers in this Article »
STJ
Shares of St Jude Medical (NYSE:STJ) have risen 10.4% since July 16, 2012 to close at $42.69 on October 11, 2012. The company is looking to keep that trend going when it releases its third quarter results on Wednesday, October 17, 2012.
Earnings play an important role in measuring the appropriate valuation for a stock. Investors should be cautious if the company's stock price is high but it consistently has low earnings. SEE: Everything Investors Need To Know About Earnings
What to Expect: Analysts are expecting St Jude Medical to report earnings of 80 cents per share, up 2.6% from a year ago, when the company reported earnings of 78 cents per share.
While down from 82 cents three months ago, the consensus estimate has remained unchanged over the past 30 days. Analysts are projecting earnings of $3.43 per share for the fiscal year.
St Jude Medical is expected to report revenue of $1.34 billion for the quarter, down by 3.1% from last year's figure of $1.38 billion. For the fiscal year, expected revenue is $5.56 billion.
Company Performance: STJ has a P/E ratio of 16.8. A simple P/E ratio can reveal the stock's real market value and show how the valuation compares to its industry group or a benchmark like the S&P 500 Index. High P/E stocks could be "growth" stocks, while low PE stocks may be "value" stocks. SEE: Can Investors Trust the P/E Ratio?
St Jude Medical's best recent streak was when its price gained $3.47 per share between September 11, 2012 and September 18, 2012.
The Competition: St. Jude Medical develops, manufactures and distributes cardiovascular medical devices. The majority of analysts (17 of 25) rate St Jude Medical a buy. They have become increasingly pessimistic about the stock, as the number of buy ratings has dropped slightly over the last three months.
The company's closest competitor in the medical equipment and supplies industry is Medtronic (MDT). Analysts are more optimistic about St Jude Medical than about Medtronic. Only 11 out of 22 analysts rate the latter a buy.
Earnings play an important role in measuring the appropriate valuation for a stock. Investors should be cautious if the company's stock price is high but it consistently has low earnings. SEE: Everything Investors Need To Know About Earnings
What to Expect: Analysts are expecting St Jude Medical to report earnings of 80 cents per share, up 2.6% from a year ago, when the company reported earnings of 78 cents per share.
While down from 82 cents three months ago, the consensus estimate has remained unchanged over the past 30 days. Analysts are projecting earnings of $3.43 per share for the fiscal year.
St Jude Medical is expected to report revenue of $1.34 billion for the quarter, down by 3.1% from last year's figure of $1.38 billion. For the fiscal year, expected revenue is $5.56 billion.
St Jude Medical's best recent streak was when its price gained $3.47 per share between September 11, 2012 and September 18, 2012.
The Competition: St. Jude Medical develops, manufactures and distributes cardiovascular medical devices. The majority of analysts (17 of 25) rate St Jude Medical a buy. They have become increasingly pessimistic about the stock, as the number of buy ratings has dropped slightly over the last three months.
The company's closest competitor in the medical equipment and supplies industry is Medtronic (MDT). Analysts are more optimistic about St Jude Medical than about Medtronic. Only 11 out of 22 analysts rate the latter a buy.
by
Investopedia Staff
Investopedia.com believes that individuals can excel at managing their financial affairs. As such, we strive to provide free educational content and tools to empower individual investors, including thousands of original and objective articles and tutorials on a wide variety of financial topics.
Free Annual Reports
